Laboratory Biomarker Analysis + Pharmacological Study + Eribulin Mesylate

1 treatment and condition followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

Laboratory Biomarker Analysis + Pharmacological Study + Eribulin Mesylate
Treatment and conditionWhere it standsTrials
Laboratory Biomarker Analysis + Pharmacological Study + Eribulin Mesylate for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1